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Abstract
Through international collaboration, we are at the start of a new age in the management of this enigmatic tumour. 
Tumours are now grouped at diagnosis using the international neuroblastoma risk grouping (INRG), which uses 
information from tumour tissue reflecting tumour biology, as well as radiology to define image-defined risk factors. 
Tumours in high-risk groups receive maximal therapy in an attempt to try and improve outcomes which are still 
poor. Intermediate-risk tumours, which have better outcomes due to better response to the current therapy, are 
treated aggressively with combination therapies with proven therapeutic effects but with increasing attention to the 
minimising adverse treatment effects. The treatment of low-risk tumours is now vastly reduced, acknowledging the 
excellent outcome in these children using minimal therapy. It has become apparent that the consequences of therapy 
in these children can easily be worse than those from the tumour itself. For very low-risk tumours, trials are exploring 
the outcomes without any treatment. INRG allows more precise comparison of results between different international 
groups and provides a template into which new prognostic variables can be introduced, and their value assessed. In 
many centres, multiarray analysis is studying the genetic profile of each tumour; perhaps, this will allow increasing 
individualisation of treatment programmes in the near future.
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Introduction
The enigma of neuroblastoma may be close to being 
solved: The spectrum of tumours from benign in some 
infants to one of the most aggressive solid tumours 
in the toddler. These are exciting times. As a result of 
stratification of risk at diagnosis, we are now starting to 
personalise therapy, sometimes escalating chemotherapy 
and introducing new combination therapies and sometimes 
reducing the therapeutic burden yet still achieving good 
outcomes.
Neuroblastoma is the most common extracranial solid 
tumour of childhood in Europe and North America, 
although the incidence is probably lower in much of Asia. 
Of all paediatric tumours, neuroblastoma has become the 
target for the most innovative approaches, either completely 
novel or by the introduction of adult agents in the younger 
age, Yet, high-risk neuroblastoma remains one of the hardest 
paediatric tumours to cure.The current therapies include 
aggressive surgical resection; chemotherapy intensification 
using myeloablative chemotherapy with stem cell rescue; 
radiotherapy to consolidate local control; immunotherapy 
and differentiation therapy. Isotope therapy is being 
explored as part of standard induction therapy, therapy for 
tumours resistant to chemotherapy and for relapse. At the 
other extreme, for low-risk tumours, only minimal therapy 
is required, and an increasing number of tumours are now 
being observed, without any interventions.
This review will focus primarily on the introduction of the 
new approach to risk grouping, an international guide to 
the selection of treatment for individual children. This is 
the template on which specific treatment modalities are 
superimposed and allows the clinician to seek out the latest 
chemotherapy, surgical or new agent advice appropriate 
for the child, he or she is treating.
Presentation and Initial Investigations
There are three main modes of presentation of 
neuroblastoma, largely a consequence of stage and site 
of the tumour:
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• Symptoms from metastatic spread
• Symptoms from the primary tumour
• Incidental finding of primary tumour
In a toddler, it is commonly the spread to bones that are 
first observed; for instance, a child who develops a limp 
or stops walking. Another typical presentation is bilateral 
periorbital swelling and bruising (‘raccoon eyes’) caused 
by soft tissue metastases. A notable feature of children 
who present with these patterns of metastatic disease is 
that they appear to be generally unwell, a consequence of 
associated bone marrow spread. Imaging of the affected 
part of the child’s body will often give an indication of 
the malignant cause, and an abdominal ultrasound and 
chest radiograph should be early investigations of any 
young child who is generally unwell, off food, with a 
haematological picture which includes anaemia but has 
ruled out leukaemia.
An infant with metastatic disease (details of MS/4S 
disease are described later) more commonly present with 
hepatomegaly which can be so gross that ventilation is 
compromised, and/or soft tissue lumps in the skin. Usual 
features of metastatic neuroblastoma in infancy are that 
the primary tumour is quite small and the bone marrow 
involvement light.
A large primary tumour may cause symptoms at any site; 
respiratory compromises if in the chest and abdominal pain 
in the abdomen, but the most concerning local event come 
from a paravertebral primary tumour which extends into 
the spinal canal. It is of concern that symptomatic spinal 
cord compression in younger children often presents 
too late for intervention to prevent permanent damage. 
Neuroblastoma should always be considered when a 
child who can walk goes of his or her legs without any 
other more obvious explanation. Urgent spinal imaging 
will demonstrate the tumour, and emergency treatment 
is indicated while the results of diagnostic investigations 
are awaited.
Most neuroblastomas can be diagnosed by the presence of 
raised urinary catecholamine metabolites (vanillylmandelic 
acid - VMA; and homovanillic acid - HMA). Urinary 
dopamine is also frequently elevated. Unlike for 
pheochromocytomas, a spot urinary analysis is adequate 
for diagnosis of neuroblastoma, not requiring a 24 h 
collection, but clinicians should be aware that raised 
catecholamines in neuroblastoma can have important 
clinical implications, causing hypertension at presentation 
and risks of circulatory disturbance during anaesthetic 
procedures, especially when the tumour is handled.
Asymptomatic tumours may be discovered incidentally. 
This is a common presentation of a non-metastatic 
thoracic primary tumour, but also adrenal tumours that 
are present at birth and can be seen on an ante-natal 
ultrasound. The general principles of management are 
the same for incidental primary tumours as for those who 
have symptoms, but antenatal adrenal tumours and those 
presenting in the neonatal period do appear to be a separate 
group due to their exceptionally good prognosis, and so 
these are considered in a separate section of this review.
For all other suspected neuroblastomas (i.e. all tumours 
presenting outside of the neonatal period), a tissue 
diagnosis is now mandatory, even if the VMA and 
HVA are elevated. This is because histological and 
biological information only obtainable from tumour tissue 
is essential to guide treatment. Initial imaging is carried 
out to decide whether a tissue biopsy should be carried out 
(metastatic or unresectable primary tumours) or attempted 
resection (localised and resectable primary tumours).
To identify metastatic spread, the current guidelines 
recommend chest computed tomography (CT) scan, bone 
marrow aspiration and trephine and metaiodobenzylguanidine 
(MIBG) scan. Bone scan may also be considered but is 
unlikely to add value to the results from the MIBG scan. 
Recommended imaging for the primary tumour is a magnetic 
resonance scan since this generally provides superior 
definition of the involvement of adjacent organs than CT. 
However, CT and ultrasound in combination will often 
provide enough information for all but the hardest cases.
Finally, there is an unusual paraneoplastic presentation of 
some very small primary neuroblastomas: Opsoclonus/
myoclonus (OM). A child presenting with OM will 
generally be referred for a neurological opinion, and 
investigation for an underlying neuroblastoma with 
urinary catecholamine assay and appropriate imaging 
should always be carried out. Many neurologists believe 
that even those in whom no neuroblastoma is identified 
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have occult neuroblasts underlying this condition, and 
the non-surgical management of those with or without 
an identified tumour is much the same. Trials are 
currently trying to establish the best treatment for this 
distressing condition. Resection of the primary tumour can 
occasionally be effective for symptom improvement, and 
so should be carried out, even though the tumour in this 
scenario does not behave in a malignant fashion.
Staging Systems and Risk Grouping
In 1971, Audrey Evans published the original staging 
system for children with neuroblastoma, critically 
recognising that neuroblastoma was unique in having a 
group of patients, the infants, who could have a metastatic 
tumour, yet with a better outcome than some with localised 
disease. She named this stage IVS, the ‘S’ standing for 
special, and this subgroup has remained special.
The unexpectedly good outcomes in infant neuroblastoma 
make it the most common reason for spontaneous tumour 
regression in humans. The other stages more traditionally 
include I–III (1-3) for localised tumours and IV (4) for 
classical metastatic disease, and overtime these have 
been modified and agreed by international committees, 
resulting in the international neuroblastoma staging 
system (INSS) in 1986 [Table 1].[1]
INSS remains the current surgical staging system, but 
over the years, there has been increasing awareness that 
surgical staging for neuroblastoma is flawed. First, patient 
outcomes are strongly influenced by the biological activity 
of the tumour, which can be extremely variable, Evans 
Stage 4s tumours being a prime example. A predictive 
classification was required to include measurement of 
biological markers. Second, it became apparent that the 
surgical approach could influence the surgical staging: The 
same large tumour crossing the midline could be Stage 1 
if resected completely, Stage 2 if incompletely resected or 
Stage 3 if just biopsied. How can one compare the impact 
of other treatments in the context of such inconsistency? 
Furthermore, case reports of infant tumours managed 
without surgery were accumulating, and these need to 
be included in staging systems to avoid exclusion bias.
In 2005, an international collaboration of neuroblastoma 
specialists met to address this issue and set up a project 
to combine datasets from all of the available national 
and international tumour registries, using survival tree 
Table 1: INSS (including 1993 modifications)[1]
Stage 1 Localised tumour with complete gross excision, with or without microscopic residual disease: Representative 
ipsilateral lymph nodes negative for tumour microscopically: Nodes attached and removed with tumour may be 
positive
Stage 2a Localised tumour with incomplete gross excision: Representative ipsilateral non‑adherent lymph nodes negative 
for tumour microscopically
Stage 2b Localised tumour with or without complete gross excision, with ipsilateral non‑adherent lymph nodes positive: 
Enlarged contralateral lymph nodes negative microscopically
Stage 3 Unresectable unilateral tumour infiltrating across the midline (beyond the opposite side of the vertebral col‑
umn) with or without regional lymph node involvement: Or midline tumour with bilateral extension through 
infiltration (unresectable) or lymph node involvement
Stage 4 Any primary tumour with dissemination to distant lymph nodes, bone, bone marrow, liver, skin and/or other 
organs (except as defined for Stage 4s disease)
Stage 4s Localised primary tumour (as defined for Stage 1, 2a or 2b disease) with dissemination limited to skin, liver and/
or bone marrow, limited to infants younger than 1 year (marrow involvement of<10% of total nucleated cells 
and MIBG scan findings negative in the tumour)
INSS: International neuroblastoma staging system, MIBG: Metaiodobenzylguanidine
Table 2: Definition of risk groups (patients with 
5‑year event‑free survival)
Very low risk (%) >85
Low risk (%) 77–85
Intermediate risk (%) 50–75
High risk (%) <50
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regression analysis of data collected on 8800 patients to 
identify the most important factors at diagnosis which 
impact on outcome.[2] Using these indicators of outcome, 
it was possible to place children with neuroblastoma into 
risk groups at diagnosis [Table 2]: High, intermediate, 
low and very low.
The analysis showed seven parameters which appear 
to have the greatest independent impact on the patient 
outcome, and as a consequence need to be scored to decide 




• Grade of tumour differentiation
• MYCN amplification
• Segmental chromosome abnormalities (LOH 11q)
• DNA ploidy.
A critical component of risk grouping at diagnosis was the 
removal of surgical staging as the method of classifying 
the primary tumour. Previous work on the relation 
between radiological definition of potential surgical risk 
factors and surgical complications in localised tumours[3] 
was extended to the assessment of all tumours. It should 
be recognised that this was a speculative step, intended 
primarily to allow comparison of data between studies. 
The presence of radiological risk factors, now referred to 
as image-defined risk factors (IDRF), does not necessarily 
equate to resectability. However, it can reasonably be 
assumed that a tumour with IDRFs will be harder to resect, 
and so surgery is likely to carry more risk. This should 
be taken into account when assessing the balance of risk 
versus benefit of resection, and increasingly, guidelines 
have suggested that if there are IDRFs at presentation, the 
tumour should be biopsied and resection only attempted 
after chemotherapy. A list of the IDRF is in Table 3.
Additional to the development of risk groups, the 
international neuroblastoma risk grouping (INRG) task 
force has achieved consensus guidance on standardisation 
of histological classification, grading of differentiation 
and genetic evaluation. This work continues, and it can be 
expected that there will be modifications to the definitions 
as more data and outcomes are analysed.
The use of IDRFs at diagnosis is incompatible with the 
use of INSS as the staging within INRG, and so the task 
force introduced a new international neuroblastoma risk 
group staging system[4] which is listed in Table 4.
Finally a complex table can be constructed to use an 
individual patient’s score from the seven prognostic 
variables to derive an estimation of which risk group the 
Table 3: Image‑defined risk factors[4]
Ipsilateral tumour within two body compartments
Neck‑chest, chest‑abdomen, abdomen‑pelvis
Neck and cervicothoracic junction
Tumour encasing carotid and/or vertebral artery and/or 
jugular vein
Tumour extending to base of skull
Tumour compressing the trachea
Tumour encasing the brachial plexus roots
Thorax
Tumour encasing the aorta and/or major branches
Tumour compressing the trachea and/or principle bronchi
Abdomen/pelvis
Tumour infiltrating the porta hepatis and/or the hepato‑
duodenal ligament
Tumour encasing the branches of the superior mesenteric 
artery at the mesenteric root
Tumour encasing the origin of the celiac axis and/or of 
the superior mesenteric artery
Tumour invading one or both of the renal pedicles
Tumour encasing the aorta and/or vena cava
Tumour encasing the iliac vessels
Pelvic tumour crossing the sciatic notch
Intraspinal tumour extension (not an IDRF if no symptoms 
or evidence of imaging of significant cord compression)
Infiltration of adjacent organs/structures
Pericardium, diaphragm, kidney, liver, mesentery
IDRF: Image‑defined risk factors
Table 4: INRG staging system[4]
L1 Localised tumour not involving vital structures as 
defined by the list of image‑defined risk factors and 
confined to one body compartment
L2 Locoregional tumour with presence of one or more 
image defined risk factors
M Distant metastatic disease (except MS)
MS Metastatic disease in child under 18 months, with 
metastases confined to skin, liver and/or bone marrow
INRG: International neuroblastoma risk grouping
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child falls into [Table 5]. Although the table appears to 
be complex, it becomes simple to use when managing a 
single patient.
High-risk Disease
As can be seen from the table, high-risk neuroblastoma 
is predominantly defined by the same characteristics 
as before the introduction of INRG: Stage 4 disease 
outside of infancy. However, the poor prognostic impact 
of MYCN amplification also features strongly in all, 
but the best prognosis localised tumours. High-risk 
treatment protocols vary in detail with regard to induction 
chemotherapy, timing of surgery and dose/extent of 
radiotherapy, but the treatment principles are the same 
for all of the major paediatric cancer collaborative groups. 
High-intensity induction chemotherapy is followed by the 
assessment of response. Failure of response to induction 
chemotherapy results in immediate introduction of the 
second-line chemotherapy. If the response is adequate at 
this and subsequent assessments generally measured by 
resolution of metastatic disease, resection of the primary 
tumour is planned. If the surgeon considers that resection 
may carry a high morbidity at this time, there is the option 
to delay surgery until later in the protocol. An example 
might be if there is a particular risk of renal insufficiency 
that might delay treatment intensification since this delay 
confers a worse overall outcome.
The surgery should attempt complete resection even if the 
tumour is still invasive and encasing major vessels such 
as the aorta. Early results from the high-risk study from 
the International Society of Paediatric Oncology suggest 
a better overall outcome if the resection is complete or 
near complete.
Before the resection stem cells are harvested, and 














L1/L2 GN maturing A: Very low
GNB intermixed
L1 Any, except NA B: Very low
GN maturing or 
GNB intermixed
Amp K: High
L2 <18 Any, except GN 
maturing or GNB 
intermixed
NA No D: Low
Yes G: Intermediate
18+ GNB nodular 
neuroblastoma
Differentiating NA No E: Low
Poorly differenti‑
ated
NA Yes H: Intermediate
Amp N: High
M <18 NA Hyperdiploid F: Low
<12 NA Diploid I: Intermediate
12–<18 NA Diploid J: Intermediate
<18 NA O: High
18+ Amp O: High
MS <18 NA No C: Very low
Yes Q: High
Amp R: High
GN: Ganglioneuroma, GNB: Ganglioneuroblastoma, Amp + amplified, NA: Not amplified
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intensification with myeloablative chemotherapy and 
stem cell rescue. Following this, there is radiotherapy, 
which may be intensified in areas where there is evidence 
of residual tumour from the tumour histology. The last 
therapeutic intervention is immunotherapy, using the 
anti-GD2 monoclonal antibody, with or without IL-2. 
All of these interventions are highly toxic and associated 
with significant morbidity. Once treatment is complete 
and assuming that the child appears to be in remission, 
maintenance differentiation therapy using 13-cis-retinoic 
acid is given since this has been shown to delay relapse 
in those who do subsequently develop recurrent disease.
The treatment burden for high-risk disease is very high, 
but this intensive regime has been shown to slowly 
improve the outcome in this terrible tumour, with 5-year 
survival steadily approaching 50%.
Low- and Intermediate-risk Disease
These tumours will be expected to show a better response 
to chemotherapy, and it is for these children that the 
stratification of treatment is so important. Historically, 
many children with low-risk disease were overtreated, 
and some will have had a worse outcome as a result of 
treatment than they would have if they had received no 
treatment at all. Localised tumours without IDRF will 
need resection at diagnosis, and some will need no further 
treatment. Tumours with IDRF at presentation, and infants 
with metastatic disease but no MYCN amplification, 
will need biopsy and chemotherapy. Some of these will 
continue to have IDRF even after chemotherapy, and in 
many of these, an observational policy is being trialled. 
However, IDRF has not been validated in this role, and 
it is for the clinical team to decide in individual cases 
whether the risks from surgery outweigh the risks from 
recurrent disease. Advice may be sought from national 
and international coordinators.
Surprisingly, MS disease can present a particularly tricky 
problem. In principle, treatment can be avoided, with the 
expectation that the primary tumour and metastases will 
spontaneously resolve. However, the gross liver disease 
can present the child with too great a tumour burden, and 
urgent intervention may be required. In this circumstance, 
the infant may be unable to tolerate even reduced or 
minimal doses of chemotherapy, and so this self-limiting 
disease can still be fatal. Application of an abdominal silo 
is sometimes required to manage abdominal compartment 
syndrome and renal failure.
Recurrent Disease
It is rare for there to be long-term survival following 
treatment of recurrent neuroblastoma. However, this is a 
fertile area for the introduction of novel strategies, and 
there are numerous new therapies which are being trialled 
in these children, hoping for a response that will introduce 
a new agent to our therapeutic array. An exciting area of 
development is with radioisotope therapy. MIBG has been 
used in a number of trials with some success, although the 
optimum use of MIBG is still being clarified. Other agents 
such as lutetium dotatate are being introduced with some 
optimism since they appear to target even drug-resistant 
neuroblasts.
Perinatal Adrenal Masses
One group of children who should be managed differently 
is those under 44 weeks gestational age at the time of 
diagnosis, who have a small (<5 cm) adrenal mass. This 
group may include some infants with other diagnoses 
such as neonatal adrenal haemorrhage, but irrespective 
of the baseline urinary catecholamine, there is now 
good evidence that it is safe to manage the whole group 
expectantly, avoiding any interventions and minimising 
investigations until the child is older. The tumour and 
catecholamines must be monitored since the rare tumour 
which is more aggressive needs to be identified, and 
treatment started. For the rest, an MIBG scan at age 
3 months will rule out metastatic disease, and if the tumour 
shrinks, then it will not need to be removed.
Conclusion
While treatment intensification is still being pursued in 
high-risk neuroblastoma, there are many tumours which 
respond to quite a low therapeutic burden, and in some, 
no treatment is required. The international collaboration 
pioneered by the INRG task force allows us to standardise 
pre-treatment classification of tumours and compare 
like with like when results from different groups are 
published. We expect this to speed up progress in treating 
neuroblastomas of all risk groups.
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